The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventory is comprised of raw materials, work in progress, and finished goods. Raw materials include purchased components and materials used in the manufacturing process, primarily API. Work in process consists of products in various stages of production. Finished goods represent completed products available for sale, VASCEPA, in 1-gram or 0.5-gram capsules. API currently has a shelf life of between four and five years. After being converted into capsule form, which is the last step in the manufacturing process, VASCEPA 1-gram and 0.5-gram capsules currently have additional shelf lives of four years and three years, respectively. Inventories as of June 30, 2026 and December 31, 2025 consist of the following:


In thousands	June 30, 2026		December 31, 2025
Raw materials	$	115,762	$	112,291
Work in process		8,366		8,201
Finished goods		39,945		75,418
Total inventory (1)	$	164,073	$	195,910

(1) During the six months ended June 30, 2026, approximately $1.7 million of inventory was expensed through cost of goods sold for product dating inventory. During both the three and six months ended June 30, 2025, approximately $0.4 million of inventory was expensed through cost of goods sold for product dating inventory.